First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors (Q27853088)
Jump to navigation
Jump to search
scientific article
- First-in-Human Phase I Study of Pictilisib (GDC-0941), a Potent Pan-Class I Phosphatidylinositol-3-Kinase (PI3K) Inhibitor, in Patients with Advanced Solid Tumors
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors |
scientific article |
|
Statements
1 reference
First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors (English)
1 reference
Joo Ern Ang
Rebecca Kristeleit
Krunal Shah
Gallia Levy
Joseph A Ware
Kathryn Mazina
Ray Lin
Jenny Wu
Jill Fredrickson
Jill M Spoerke
Yibing Yan
Lori S Friedman
Stan B Kaye
Mika K Derynck
Johann S de Bono
1 January 2015
0 references
1 reference
1 reference
1 reference
Identifiers
2 references
2 references
2 references